- Therma Bright (THRM) is preparing to launch DCT, its digital cough data collection and screening smartphone application
- The company is partnering with AI4LYF, a smart-health company that is also working on AI based novel solutions
- Therma Bright acquired exclusive worldwide licensing rights to market and sell products based on AI4LYF’s Digital Cough Technology, which can be used to record and collect cough sounds using a smartphone
- Therma Bright (THRM) opened trading at $0.07 per share
Therma Bright (THRM) is preparing to launch DCT, its digital cough data collection and screening smartphone application.
The company is partnering with AI4LYF, a smart-health company that is also working on AI based novel solutions that have potential to change the “reactive Sick care” into “predictive, preventive, personalized health care”.
Therma Bright acquired exclusive worldwide licensing rights to market and sell products based on AI4LYF’s Digital Cough Technology (DCT). This proprietary mobile app can be used to record and collect cough sounds using a smartphone. With AI-machine learning technology, DCT can detect the subtle and specific signatures of a variety of respiratory diseases through changes in cough features.
Several studies have shown that cough severity is correlated with disease activity in asthma and a range of other respiratory diseases.
AI4LYF’s founder, Dr. Ali Imran explained that Therma Bright will initially make the smartphone application available through healthcare practitioners to be used as a general educational tool, so individuals become more aware of the nature and frequency of their cough.
“In the second phase, cough samples will be collected from patients with confirmed respiratory diseases.”
Therma Bright’s CEO, Rob Fia added that after speaking with United States Food & Drug Administration (FDA) and Health Insurance Portability and Accountability Act (HIPPA) experts, the team intends to finalize launch plans in the United States and Canada to initiate large scale collection of cough sounds from the general population.
“The ultimate goal is to develop a mobile app than can identify different types of respiratory conditions solely from the cough sounds.”
Therma Bright is a developer and partner in a range of leading-edge, proprietary diagnostic and medical device technologies focused on important medical and healthcare challenges.
Therma Bright (THRM) opened trading at $0.07 per share.
